Medinice SA (ICE) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PLN 101 Million ()

P/E

2.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.01

Return on Equity

48.14%

Price to Book

1.30

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

10.43%

6 Months

86.4%

1 Year

85.9%

2 Years

41.78%

3 Years

5.91%

4 Years

-33.11%

5 Years

-22.33%

Medinice SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-10.01%

EBIT Growth (5y)

-180.27%

EBIT to Interest (avg)

-3.87

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.08

Sales to Capital Employed (avg)

0.00

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

9.43%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.15

EV to EBIT

-18.44

EV to EBITDA

-19.54

EV to Capital Employed

1.15

EV to Sales

87.96

PEG Ratio

Dividend Yield

ROCE (Latest)

-6.26%

ROE (Latest)

47.43%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 0.00% vs -100.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -102.69% vs 4,644.44% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.10",
          "val2": "-1.00",
          "chgp": "-10.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.10",
          "val2": "40.90",
          "chgp": "-102.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-56,526.30%",
          "chgp": "5,652.63%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 837.25% vs -4.08% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.40",
          "val2": "-5.40",
          "chgp": "18.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "41.90",
          "val2": "-0.20",
          "chgp": "21,050.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "37.60",
          "val2": "-5.10",
          "chgp": "837.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-24,792.60%",
          "val2": "-25,280.00%",
          "chgp": "48.74%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Mar'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.10

-1.00

-10.00%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-1.10

40.90

-102.69%

Operating Profit Margin (Excl OI)

0.00%

-56,526.30%

5,652.63%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2025 is 0.00% vs -100.00% in Dec 2024

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is -102.69% vs 4,644.44% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.20

Operating Profit (PBDIT) excl Other Income

-4.40

-5.40

18.52%

Interest

0.10

Exceptional Items

41.90

-0.20

21,050.00%

Consolidate Net Profit

37.60

-5.10

837.25%

Operating Profit Margin (Excl OI)

-24,792.60%

-25,280.00%

48.74%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 837.25% vs -4.08% in Dec 2023

All Annual Results

Company CV

About Medinice SA

Medinice SA

Pharmaceuticals & Biotechnology

Medinice SA is a Poland-based company engaged in medical diagnostic and testing equipment business sector. The Company specializes in creating, developing and commercializing safe and minimally invasive solutions in the field of medicine, in particular cardiology and cardio surgery. Its portfolio comprises of projects, such as CathAIO, Cryoapplicator, Med-IConsole, Minimax, Pacepress and others. All of the Company's projects have a global potential. The Company cooperates with research centers in Poland and Europe. It strives to commercialize inventions brought by both co-founders of the Company and acquired projects through the sale of licenses worldwide in the production of medical devices.

Company Coordinates

Company Details

Ul. Chmielna 132/134 , WARSZAWA None : 00-805

Tel:

http://www.medinice.pl/

Registrar Details